These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Proinflammatory Cytokine Environments Can Drive Interleukin-17 Overexpression by γ/δ T Cells in Systemic Juvenile Idiopathic Arthritis. Kessel C; Lippitz K; Weinhage T; Hinze C; Wittkowski H; Holzinger D; Fall N; Grom AA; Gruen N; Foell D Arthritis Rheumatol; 2017 Jul; 69(7):1480-1494. PubMed ID: 28296284 [TBL] [Abstract][Full Text] [Related]
10. Reversal of Sepsis-Like Features of Neutrophils by Interleukin-1 Blockade in Patients With Systemic-Onset Juvenile Idiopathic Arthritis. Ter Haar NM; Tak T; Mokry M; Scholman RC; Meerding JM; de Jager W; Verwoerd A; Foell D; Vogl T; Roth J; Leliefeld PHC; van Loosdregt J; Koenderman L; Vastert SJ; de Roock S Arthritis Rheumatol; 2018 Jun; 70(6):943-956. PubMed ID: 29426067 [TBL] [Abstract][Full Text] [Related]
11. Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis. Saccomanno B; Tibaldi J; Minoia F; Bagnasco F; Pistorio A; Guariento A; Caorsi R; Consolaro A; Gattorno M; Ravelli A J Rheumatol; 2019 Apr; 46(4):416-421. PubMed ID: 30647180 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ; Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Vastert SJ; de Jager W; Noordman BJ; Holzinger D; Kuis W; Prakken BJ; Wulffraat NM Arthritis Rheumatol; 2014 Apr; 66(4):1034-43. PubMed ID: 24757154 [TBL] [Abstract][Full Text] [Related]
17. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924 [TBL] [Abstract][Full Text] [Related]
18. Systemic Juvenile Idiopathic Arthritis: Diagnosis and Management. Kumar S Indian J Pediatr; 2016 Apr; 83(4):322-7. PubMed ID: 26916892 [TBL] [Abstract][Full Text] [Related]
19. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Nigrovic PA Arthritis Rheumatol; 2014 Jun; 66(6):1405-13. PubMed ID: 24623686 [No Abstract] [Full Text] [Related]
20. Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis. Baris HE; Anderson E; Sozeri B; Dedeoglu F Clin Rheumatol; 2018 Dec; 37(12):3263-3273. PubMed ID: 30238379 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]